This insider cluster is routine and non-informational, the sales are tied to option exercises and tax withholding, not a bearish signal. Monitor for any upcoming earnings or pipeline updates, but this filing alone does not warrant a trading action.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 21 $535.83entry
- T+1 · 4mo ago −1.63%α −1.52% · $527.07
- T+5 · 4mo ago −2.28%α −1.29% · $523.63
- T+20 · 3mo ago −3.28%α −5.84% · $518.27
- T+60 · 5w ago +0.78%α −2.07% · $540.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A cluster of insider sales at United Therapeutics shows the CEO and General Counsel selling shares, primarily to cover tax obligations from exercised options. The total open-market sales of ~$349K represent a trivial 0.0015% of the $22.7B market cap, making this a routine, non-informational event.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold ~$4.5M in open-market shares on July 17, 2026, but these were part of a larger option exercise (9,500 shares at $0) and a cash exercise (9,500 shares at $135.42), with the sales primarily covering tax withholding.
- EVP Paul Mahon sold ~$1.8M in open-market shares on July 16, 2026, also tied to option exercises (8,300 shares at $146.03 and 8,300 shares at $0).
- Director Jan Malcolm sold $179K in open-market shares on July 10, 2026, a standalone sale not linked to option exercises.
- Total open-market sales in the cluster are ~$349K, which is 0.0015% of UTHR's $22.7B market cap, a trivial amount.
- The 30-day insider activity shows 9 sells totaling $4.8M, consistent with routine option exercise and tax-related selling patterns.
Financial Impact
Total open-market sales of ~$349K, representing 0.0015% of market cap. No material financial impact.
Risk Factors
- Insider selling patterns could intensify if the stock continues to appreciate, but current volume is trivial.
- No material risk identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1784613717929 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers